GlassScriptPhysician profile
Shamin A Salman
NPI 1649221417
$10,606.75
in general payments reported to CMS, 2019-2025
46 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $645 · 2021: $1,561 · 2022: $1,992 · 2023: $2,015 · 2024: $1,488 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,924 · Consulting Fee: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,923.80 |
| Consulting Fee | $159.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,093.79 | 2019-2025 | |
| Amgen INC. | $939.08 | 2019-2023 | Lumakras, Kyprolis, Xgeva |
| Incyte Corporation | $806.51 | 2019-2025 | Jakafi, Jakafi |
| Glaxosmithkline, LLC. | $805.56 | 2022-2025 | Nucala, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $650.56 | 2019-2025 | Libtayo |
| Genzyme Corporation | $526.59 | 2019-2025 | |
| Gilead Sciences, INC. | $485.87 | 2021-2024 | Trodelvy |
| Janssen Biotech, INC. | $435.75 | 2019-2023 | Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $394.12 | 2023-2025 | Fruzaqla |
| Merck Sharp & Dohme LLC | $333.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $296.32 | 2019-2025 | Tagrisso, Enhertu, Lynparza |
| Beigene USA, INC. | $236.44 | 2022-2025 | Brukinsa |
| Eisai INC. | $220.55 | 2022-2025 | |
| Pfizer INC. | $220.51 | 2019-2025 | |
| Daiichi Sankyo INC. | $194.72 | 2022-2024 | Enhertu |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamin Salman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.